# FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	VAL
OMB Number:	3235-0287
Estimated average bu	ırden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

#### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Typ	pe Responses	s)													
1. Name and Address of Reporting Person *- McWherter Charles				2. Issuer Name and Ticker or Trading Symbol CymaBay Therapeutics, Inc. [CBAY]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director X Officer (give title below) Other (specify below)  Sr. Vice President				
(Last) (First) (Middle) C/O CYMABAY THERAPEUTICS, INC., 7999 GATEWAY BLVD, SUITE 130				3. Date of Earliest Transaction (Month/Day/Year) 12/30/2016											
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_ Fo	6. Individual or Joint/Group Filing(Check Applicable Line)  _X_Form filed by One Reporting Person  Form filed by More than One Reporting Person				
	K, CA 9456		271.)								on med by r	viore man one i	Reporting Person		
(City	")	(State)	(Zip)			Tab	le I -	Non-Derivat	ive Securities	Acquired, 1	Disposed	of, or Bene	ficially Owner	d	
1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Year				Execution Date, if Code			(A) (Ins	ecurities Acqui or Disposed of tr. 3, 4 and 5)  (A) or (D)	(D) Owne Trans		Fc Di or (I)		wnership orm: herect (D) Indirect (In	neficial vnership	
Reminder: I	Report on a se	eparate line for each	n class of securities	beneficial	lly o	wned dire	ectly	or indirectly.							
								contained	who respond in this form lays a curre	n are not r	equired	to respon	d unless the	SEC 147	74 (9-02)
									d of, or Benef ertible securit		ied				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security			Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)			9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Beneficial
							, 4,						(Instr. 4)	(Instr. 4)	
				Code	V		(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	

#### Reporting Owners

Reporting Owner Name / Address	Relationships					
reporting 6 mer runner runners	Director	10% Owner	Officer	Other		
McWherter Charles C/O CYMABAY THERAPEUTICS, INC. 7999 GATEWAY BLVD, SUITE 130 NEWARK, CA 94560			Sr. Vice President			

### **Signatures**

/s/ Sujal Shah, by power of attorney	01/04/2017
**Signature of Reporting Person	Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On July 25, 2016, the Reporting Person was granted an option to purchase 46,000 shares of common stock of the Issuer. The option vests in two equal installments based on the Issuer's achieving certain milestones. The first milestone was met, resulting in vesting of the option as to 23,000 shares.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.